treatment

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study

Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..

Biogen Reports Positive Results on Alzheimer's Trial, Shares Soar

Biogen Reports Positive Results on Alzheimer's Trial, Shares Soar

Biogen Inc. (NASDAQ: BIIB) announced today that the outcome of its large clinical trial consisting of 856 patients regarding an Alzheimer’s drug produced positive results. Together with its Japanese partner, Eisai Co., the experimental dr..

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..